Global Cervical Cancer Pipeline Landscape 2025

DelveInsight's "Cervical Cancer Pipeline Analysis 2025" delivers extensive intelligence on over 70 pharmaceutical firms and more than 70 investigational medications within the Cervical Cancer development arena. The analysis encompasses profiles of Cervical Cancer therapeutic candidates, spanning both clinical and preclinical phases. Additionally, it includes evaluation of Cervical Cancer therapeutics by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant development programs in this therapeutic area.

Access DelveInsight's comprehensive Cervical Cancer Pipeline Analysis to examine emerging therapies, key companies, and future Cervical Cancer treatment landscapes @ Cervical Cancer Pipeline Outlook Report

Primary Highlights from the Cervical Cancer Pipeline Analysis

• On November 5, 2025, Memorial Sloan Kettering Cancer Center revealed an investigation to determine if ivonescimab is an effective treatment for individuals with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also examine whether the investigational medication is safe and causes minimal or mild side effects in participants.

• On October 30, 2025, Merck Sharp & Dohme LLC initiated an investigation comprising two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 segment. The safety run-in phase will be utilized to evaluate the efficacy and safety profile of sacituzumab tirumotecan at the dose for assessment in the Phase 3 segment. The objective of this investigation is to compare the efficacy and safety of sacituzumab tirumotecan versus treatment of physician's choice as second-line treatment for participants with recurrent or metastatic cervical cancer in the Phase 3 segment.

• DelveInsight's Cervical Cancer pipeline analysis reveals a dynamic field featuring more than 70 engaged entities advancing over 70 investigational treatments for Cervical Cancer management.

• Major Cervical Cancer pharmaceutical firms include Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, AnGes, Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine - National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics, among additional organizations.

• Notable Cervical Cancer investigational medications include Granisetron, Ondansetron, Sorafenib, Cisplatin, Gemcitabine, among others.

Access DelveInsight's in-depth Cervical Cancer Pipeline Analysis for a closer examination of promising breakthroughs @ Cervical Cancer Clinical Trials and Studies

Cervical Cancer Background

Cervical cancer remains the fourth most prevalent cancer in developing nations. It develops in a woman's cervix (the entrance to the uterus from the vagina) and occurs when the cells on the cervix begin to transform into precancerous cells. Not all precancerous cells will progress to cancer, but identifying these problematic cells and treating them before they can transform is critical to preventing cervical cancer. Early stages of cervical cancer typically don't involve symptoms and are challenging to detect. The initial signs of cervical cancer may take several years to develop. Some symptoms of cervical cancer include: Watery or bloody vaginal discharge that may be heavy and can have a foul odor, Vaginal bleeding after intercourse, between menstrual periods or after menopause, Menstrual periods may be heavier and last longer than normal. Screening with a Pap test can detect most cases of cervical cancer that collects cells from the cervix as well as tests for Liver, kidney, Blood, urine tests, X-rays are also needed. The treatments for cervical cancer are radiation, chemotherapy, surgery, targeted therapy and immunotherapy.

Cervical Cancer Investigational Drug Profiles

Axalimogene filolisbac: Advaxis

Axalimogene filolisbac is a type of cancer vaccine under development as immunotherapy that targets HPV-associated cancers such as cervical cancers. It functions by alerting the body's immune system to the presence of cancer, stimulating the body's natural defenses to attack the cancer. Axalimogene filolisbac is administered intravenously and is under development for managing persistent, recurrent, or metastatic, squamous or non-squamous cell cervical cancer in patients who progress beyond first-line Phase III Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV therapy. If licensed, Axalimogene filolisbac will offer a new therapeutic option for this patient group.

Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.

Camrelizumab (AiRuiKaTM), a programmed cell death 1 (PD-1) inhibitor under development by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for managing relapsed or refractory classical Hodgkin lymphoma. The medication is also under investigation as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer. The medication is presently undergoing Phase III clinical trial assessment for cervical cancer management.

AK104: Akeso

Cadonilimab (AK104) is a novel, potential next-generation, first-in-class bi-specific PD-1/CTLA-4 immuno-oncology backbone drug independently created by the Company, and its major indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell cancer and nasopharyngeal carcinoma. The preliminary research data of cervical cancer, gastric cancer and other tumors demonstrates that, as compared with the combination therapy of PD-1 and CTLA-4, Cadonilimab has significantly lower toxicity and demonstrated promising safety profile and efficacy. In September 2020, National Medical Products Administration (the NMPA) of China has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and development code: AK104) for managing relapsed or metastatic cervical cancer, which has received priority review.

Durvalumab: AstraZeneca

A medication that binds to the protein PD-L1 to help immune cells kill cancer cells better and is used to manage different types of cancer. Durvalumab is used alone or with other medications to manage adults with certain types of extensive-stage small cell lung cancer or stage III non-small cell lung cancer. It is also under investigation for managing other types of cancer. Durvalumab may block PD-L1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. A Phase III clinical trial is being conducted for durvalumab to manage patients with cervical cancer.

HLX10: Shanghai Henlius Biotech

HLX10, a novel recombinant humanised anti-programmed cell death protein 1 (PD-1) mAb independently created by Henlius, has the potential to manage a variety of solid tumours. HLX10 has exhibited superior pharmacokinetics, pharmacodynamics properties, favourable safety, tolerability profile and anti-tumor activity in preclinical and early clinical research studies. It is presently under investigation in Phase II developmental stage to provide the potential treatment for cervical cancer.

The Cervical Cancer Pipeline Analysis Offers Intelligence On

• The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Cervical Cancer management, including cumulative therapies created by each organization for this indication.

• It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Cervical Cancer Treatment.

• Cervical Cancer pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.

• Cervical Cancer investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.

• Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Cervical Cancer market.

Obtain a comprehensive analysis of the latest innovations in the Cervical Cancer pipeline. Examine DelveInsight's expert-driven analysis today! @ Cervical Cancer Unmet Needs

Cervical Cancer Pharmaceutical Firms

Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, AnGes, Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine - National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics, among additional organizations.

The Cervical Cancer pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Cervical Cancer products are classified under various molecular categories including:

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Access DelveInsight's latest analysis to gain strategic insights into upcoming Cervical Cancer Therapies and key developments @ Cervical Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Cervical Cancer Pipeline Analysis

• Coverage: Global

• Cervical Cancer Pharmaceutical Firms: Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, AnGes, Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine - National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics, among additional organizations.

• Cervical Cancer Investigational Treatments: Granisetron, Ondansetron, Sorafenib, Cisplatin, Gemcitabine, among others.

• Cervical Cancer Therapeutic Evaluation by Product Category: Monotherapy, Combination, Mono/Combination

• Cervical Cancer Therapeutic Evaluation by Clinical Phases: Discovery, Preclinical, Phase I, Phase II, Phase III

Which companies are pioneering the advancement in Cervical Cancer drug development? Discover in DelveInsight's exclusive Cervical Cancer Pipeline Analysis @ Cervical Cancer Emerging Drugs and Major Companies

Table of Content

• Introduction

• Executive Summary

• Cervical Cancer: Background

• Pipeline Therapeutics

• Therapeutic Evaluation

• Cervical Cancer - DelveInsight's Analytical Perspective

• Late Phase Products (Phase III)

• Axalimogene filolisbac: Advaxis

• Drug profiles in the comprehensive report.....

• Mid Phase Products (Phase II/III)

• QL 1604: Qilu Pharmaceutical

• Drug profiles in the comprehensive report.....

• Early Phase Products (Phase I/II)

• NP 137: Netris Pharma

• Drug profiles in the comprehensive report.....

• Early Phase Products (Phase I)

• RTX 321: Rubius Therapeutics

• Drug profiles in the comprehensive report.....

• Inactive Products

• Cervical Cancer Key Pharmaceutical Firms

• Cervical Cancer Key Products

• Cervical Cancer- Unaddressed Medical Needs

• Cervical Cancer- Market Drivers and Obstacles

• Cervical Cancer- Future Outlook and Conclusion

• Cervical Cancer Analyst Perspectives

• Cervical Cancer Key Pharmaceutical Firms

• Appendix

About Us

DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.

Contact Us

Kanishk

kkumar@delveinsight.com